

## AMENDMENTS TO THE CLAIMS

### WHAT IS CLAIMED:

1. **(Currently Amended)** An implant for treating glaucoma, comprising:  
a body comprising material that includes a therapeutic drug, said body having an inlet portion and an outlet portion, said inlet portion configured to reside in the anterior chamber of an eye when the outlet portion is disposed in ~~Schlemm's canal~~ a physiological outflow pathway of the eye, said outlet portion having an outflow opening such that said body transports fluid from the anterior chamber to the physiological outflow pathway~~Schlemm's canal~~.
2. **(Currently Amended)** The implant of Claim 1, wherein said body is coated with said therapeutic drug.
3. **(Original)** The implant of Claim 1, wherein said drug comprises heparin.
4. **(Currently Amended)** An implant for treating glaucoma, comprising:  
a body having a ~~bioactive agent~~ therapeutic drug in or on said body, said body having an inlet portion and an outlet portion, said inlet portion configured to transmit fluid from the anterior chamber to the outlet portion when the outlet portion is disposed in a physiological outflow pathway~~Schlemm's canal~~, said outlet portion having an outflow opening.
5. **(Currently Amended)** The implant of Claim 4, wherein said body is coated with said ~~bioactive agent~~ therapeutic drug.
6. **(Currently Amended)** The implant of Claim 4, wherein said ~~bioactive agent~~ therapeutic drug comprises heparin.
- 7.-45. **(Cancelled)**
46. **(New)** The implant of Claim 1, wherein the physiological outflow pathway is Schlemm's canal.
47. **(New)** The implant of Claim 4, wherein the physiological outflow pathway is Schlemm's canal.
48. **(New)** A method of treating glaucoma, comprising:  
introducing an implant comprising a therapeutic drug into the anterior chamber of an eye; and

**Appl. No.** : 10/706,300  
**Filed** : November 12, 2003

advancing said implant into eye tissue adjacent the anterior chamber such that the implant drains aqueous humor from the anterior chamber into a physiological outflow pathway and the therapeutic drug reaches eye tissue in which the implant is implanted.

49. **(New)** The method of Claim 48, wherein the implant is coated with said therapeutic drug.